Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pain Therapeutics (PTIE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 23,395
  • Shares Outstanding, K 6,590
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,850 K
  • 36-Month Beta 2.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +3.39%
on 07/19/17
4.25 -13.88%
on 06/28/17
-0.34 (-8.50%)
since 06/23/17
3-Month
3.39 +7.96%
on 06/02/17
5.95 -38.49%
on 04/28/17
-1.73 (-32.10%)
since 04/24/17
52-Week
3.39 +7.96%
on 06/02/17
21.00 -82.57%
on 09/20/16
-14.82 (-80.19%)
since 07/22/16

Most Recent Stories

More News
CGlobal Pain Therapeutics Report 2017 - Drugs, Markets and Companies Projections to 2026

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [https://www.researchandmarkets.com/research/nl9g9s/pain_therapeutics]...

PTIE : 3.66 (+3.10%)
CGlobal Pain Therapeutics Report 2017 - Drugs, Markets and Companies Projections to 2026

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.

PTIE : 3.66 (+3.10%)
Breakfast Technical Briefing on Biotech Stocks -- Opko Health, Pain Therapeutics, Trevena, and Dynavax Technologies

If you want a stock review on OPK, PTIE, TRVN, or DVAX then come over to http://dailystocktracker.com/register/ and sign up for your free customized reports today. This morning, DailyStockTracker.com turns...

TRVN : 2.96 (+7.44%)
PTIE : 3.66 (+3.10%)
DVAX : 10.65 (+10.94%)
OPK : 6.44 (-2.28%)
NIH Awards $1.7 Million Research Grant to Pain Therapeutics to Study Alzheimer's Disease

Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today announced that the National Institutes of Health (NIH) has awarded the Company a $1.7 million research grant to study PTI-125,...

PTIE : 3.66 (+3.10%)
Pain Therapeutics Announces Research Publication on Alzheimer's Disease

Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today announced a technical publication authored by its scientists and academic collaborators that further demonstrates a potentially...

PTIE : 3.66 (+3.10%)
Pain Therapeutics Report (2017-2026) - Assessment of Pain & Analgesics - Research and Markets

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.

PTIE : 3.66 (+3.10%)
Global 2017 Pain Therapeutics Drugs, Markets and Companies Report 2017 - Projections to 2026

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.

PTIE : 3.66 (+3.10%)
Pain Therapeutics Report (2017-2026) - Profiles of 173 Companies & 153 Collaborations - Research and Markets

DUBLIN, April 06, 2017 /PRNewswire/ --

PTIE : 3.66 (+3.10%)
Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY(TM) ER

Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced positive regulatory guidance from a recent meeting with the U.S. Food and Drug Administration (FDA) regarding REMOXY (extended-release oxycodone capsules...

PTIE : 3.66 (+3.10%)
Pain Therapeutics Attendee List Released Featuring Scientific Leaders and Top Industry Experts

Aimed at capturing the latest clinical developments in pain management, SMi Group's timely Pain Therapeutics summit will gather an audience of scientific pioneers and industry experts when it takes place...

PTIE : 3.66 (+3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Pain Therapeutics is developing a new generation of opioid painkillers.Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical...

See More

Support & Resistance

2nd Resistance Point 3.82
1st Resistance Point 3.74
Last Price 3.66
1st Support Level 3.57
2nd Support Level 3.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.